نتایج جستجو برای: alteplase
تعداد نتایج: 6831 فیلتر نتایج به سال:
TheUKMedicines and Healthcare Products Regulatory Agency has announced it is to review the “balance of benefits and risks” of the use of alteplase in the treatment of acute ischaemic stroke. In a letter published in the Lancet on 23 August, Ian Hudson, chief executive of the MHRA, announced that the agency was setting up a panel of experts to review “any new information or concerns about the da...
Introduction: Alteplase is widely used as an intravenous thrombolytic drug in acute ischemic stroke (AIS). Recently however, tenecteplase, a modified form of tissue plasminogen activator, has been shown to increase early recanalization rate and proven be non-inferior with similar safety profile compared alteplase. This study aims evaluate the cost-effectiveness 0.25 mg/kg tenecteplase versus 0....
The third International Stroke Trial (IST-3) is the largest (n=3035) randomised controlled trial of intravenous alteplase for acute ischaemic stroke to date. 1 Participants in IST-3 were older than in previous trials: 1617 (53%) were older than 80 years of age, whereas only 112 patients of this age were included in eight previous similar trials. 2 In IST-3, participants could be treated up to 6...
Alteplase, tissue type plasminogen activator,t-PA has been the gold standard for fibrinolytic therapy in acute ischaemic stroke, approved for use by FDA within 3 hours of symptom onset. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, with prolonged plasma half life and higher fibrin selectivity, has emerged as a promising alternative intravenous alteplase. This artic...
BACKGROUND AND PURPOSE The effects of delayed thrombolysis with alteplase and neuroprotection with an excitatory amino acid receptor antagonist and their combination were tested in an embolic stroke model. METHODS In 61 rats the carotid artery territory was embolized with arterial-like fibrin-rich clots. Hemispheric cerebral blood flow before and after embolization was measured by intra-arter...
BACKGROUND The effectiveness of specific systems changes to reduce DTN (door-to-needle) time has not been fully evaluated. We analyzed the impact of 4 specific DTN time reduction strategies implemented prospectively in a staggered fashion. METHODS AND RESULTS The HASTE (Hurry Acute Stroke Treatment and Evaluation) project was implemented in 3 phases at a single academic medical center. In HAS...
BACKGROUND AND PURPOSE According to the European license, alteplase can be given no sooner than 3 months after previous stroke. However, it is not known whether past history of stroke influences the effect of treatment. Our aim was to evaluate safety and functional outcome after intravenous thrombolysis administered in everyday practice to patients with previous stroke≤3 months compared with th...
BACKGROUND In acute myocardial infarction patients who do not reperfuse their infarct arteries shortly after thrombolytic treatment have a high morbidity and mortality. Management of this high risk group remains problematic, especially in centres without access to interventional cardiology. Additional thrombolytic treatment may result in reperfusion and improved left ventricular function. MET...
A embolia pulmonar (EP) tardia na COVID-19 é aquela que ocorre semanas após a infecção pelo SARS-CoV-2 e vem sendo relatada mesmo nos pacientes manifestaram síndrome gripal leve. Não há explicação fiável para sua ocorrência, mas parece envolver persistência das alterações inflamatórias virais associadas à exposição de fosfolipídios liberação micropartículas membrana potencialmente trombogênicas...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید